Bob Smith said:
Quote:
Originally Posted by greyowl
But I do conclude from my own experience
You chastise me for saying I think natural GH manipulation is bunk, and yet you come back with a similar anecdotal arguement
My actual statement was as follows (emphasis mine)
"But I do conclude from my own experience AND MY MEDLINE SEARCHES ..." thus indicating that my deductions were based on clinical studies as well my personal observation.
With regard to the Yarasheski studies and your comment
Bob Smith said:
both of those quotes are with injected GH! So if injectible GH doesnt work very well, how can you (or your former gf) postulate that natural GH swings are worth a shit?"
I postulate this because there are several papers that contradict Yarasheski's findings, so the debate about this isssue is clearly not over. I've cited one study in an earlier post, and append two more abstracts at the end this post.
I'll post some of my hypotheses about why I think Yarasheski's studies aren't conclusive later in the week when I get home from a business trip.
Here are the two other abstracts.
Aging 1997 Jun;9(3):193-7.
Effects of six-month administration of recombinant human growth hormone to healthy elderly subjects.
Cuttica CM, Castoldi L, Gorrini GP, Peluffo F, Delitala G, Filippa P, Fanciulli G, Giusti M.
DISEM, Cattedra di Endocrinologia, University of Genova, Italy.
In aging, both changes in body composition and a decrease in GH secretion are observed. While recombinant human GH (rhGH) therapy was shown to be effective in GH-deficient adults, its effects on normal aging are controversial. This study addressed the effects of six-month administration of low dosages of rhGH in a group of 5 healthy elderly subjects (age range 71-86 years). All subjects received 2 IU rhGH (Saizen, Serono) x 2/week s.c., which was approximately 0.03 mg/kg/week, and were examined before and 1, 3, and 6 months after the start of the therapy, as well as 3 months after therapy was suspended. Hormonal, metabolic and biochemical parameters, as well as bone density at the forearm level, body composition and muscle strength, assessed by isokinetic exercises, were evaluated at each scheduled visit. After the start of the therapy, there was an average 9 +/- 3% increase (median 8%) in IGF-I levels (IGF-I basal: 145.6 +/- 9 ng/mL, IGF-I peak: 176.0 +/- 10; p < 0.001). An increase in lean body weight, a decrease in fat (p < 0.05), and an improvement in muscle strength (p < 0.01) were recorded.
--------------------------
Horm Res. 2004;62 Suppl 4:23-30.
Long-term challenges in growth hormone treatment.
Leal Cerro A.
Department of Endocrinology, Hospital Universitario Virgen del Rocio, Hospital General, Sevilla, Spain.
alfonso.leal.sspa@juntadeandalucia.es
Growth hormone deficiency (GHD) is defined biochemically as a response to hypoglycaemia with a peak GH concentration of less than 5 microg/l. The 'GHD syndrome' is a range of psychological and physical symptoms that are associated with GHD, which include increased central adiposity, decreased bone mineral density, abnormal lipid profiles, decreased cardiovascular performance, reduced lean body mass (LBM), social isolation, depressed mood and increased anxiety. Importantly, the combination of physical and psychological problems can often result in a reduced quality of life. A number of trials have shown that GH replacement therapy can lead to a substantial improvement in GHD associated symptoms. Following up to 12 months of treatment with GH, LBM increased, left ventricular systolic function improved and the mean volume of adipose tissue fell. After only 4 months of treatment, a rise in exercise capacity was recorded, and after 2 years' treatment, isokinetic and isometric muscle strength had normalized in proximal muscle groups.